Drugs for Alzheimer's disease: Cholinesterase inhibitors have passed NICE's hurdle

BMJ

Volumn 323, Issue 7305, 2001, Pages 123-124

  O'brien, John T ^a   Ballard, Clive G ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; COGNITION; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HEALTH SERVICE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; NOOTROPIC AGENTS; PRACTICE GUIDELINES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0035928471     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.323.7305.123     Document Type: Editorial

References (12)

1. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, et al. The prevalence of dementia in Europe: a collaborative study of 1980–1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991; 20: 736–748.
2. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Psychol Med 1998; 28: 319–335.
3. Audit Commission. Forget me not. Portsmouth: Holbrooks, 2000
4. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457–1459.
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group Neurology 1998; 50: 136–145.
6. Corey-Bloom J, Anand R, Veach J. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatric Psychopharmacol 1998; 1: 55–65.
7. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633–638.
8. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–2268.
9. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–2276.
10. Matthews H, Korbey J, Wilkinson D, Rowden J. Donepezil in Alzheimer's disease—eighteen months results from Southampton Memory Clinic. Int J Geriatric Psychiatry (in press).
11. Allen H. Anti-dementia drugs [editorial]. Int J Geriatric Psychiatry 1999; 14: 239–243.
12. Whitehouse PJ, Winblad B, Shostak D, Bhattacharjya A, Brod M, Brodaty H, et al. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Alzheimer Disease and Associated Disorders 1998; 12: 266–280.